Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL
Sign Up to like & getrecommendations! Published in 2018 at "Diabetes Care"
DOI: 10.2337/dc18-1871
Abstract: OBJECTIVE The sodium–glucose cotransporter 2 inhibitors (SGLT2i) empagliflozin and canagliflozin reduce the incidence of major adverse cardiovascular events (MACE), all-cause mortality (ACM), and renal events in cardiovascular outcomes trials, with observational real-world evidence suggesting class… read more here.
Keywords: class; placebo arm; sglt2i users; sglt2i ... See more keywords